Eculizumab as Salvage Treatment for Thrombotic Microangiopathy After Lung Transplantation
Fuente:
Wiley Open Access
Guardado en:
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Artículo Open Access |
| Publicado: |
Wiley
2024
|
| Materias: | |
| Acceso en línea: | |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| _version_ | 1867005406402838528 |
|---|---|
| author | Hernando Trujillo Ana Huerta Rodrigo Alonso Maria Luisa Serrano Myriam Aguilar Enrique Morales Teresa Cavero |
| author_facet | Hernando Trujillo Ana Huerta Rodrigo Alonso Maria Luisa Serrano Myriam Aguilar Enrique Morales Teresa Cavero Hernando Trujillo Ana Huerta Rodrigo Alonso Maria Luisa Serrano Myriam Aguilar Enrique Morales Teresa Cavero |
| collection | Wiley Open Access |
| contents | Eculizumab as Salvage Treatment for Thrombotic Microangiopathy After Lung Transplantation Hernando Trujillo Ana Huerta Rodrigo Alonso Maria Luisa Serrano Myriam Aguilar Enrique Morales Teresa Cavero Clinical Transplantation ABSTRACTBackgroundThrombotic microangiopathy (TMA) is a rare complication after lung transplantation (LT) that has seldom been characterized in detail. Recent evidence has linked TMA other than primary atypical hemolytic uremic syndrome (aHUS) with hyperactivation of the complement alternative pathway. The focus of this investigation was to analyze the treatment response with eculizumab in TMA after LT.MethodsCase series where we have studied 11 patients with TMA after LT from 2 Spanish tertiary healthcare centers. Clinical data and response rates to eculizumab are provided.ResultsThe main indication for lung transplant was chronic obstructive pulmonary disease (COPD) (36%) and most cases (82%) received bilateral LT. The median time to TMA diagnosis was 11.6 months (4.7–28.9) and the TMA trigger in the majority of cases (73%) was immunosuppressive drugs. Platelet and hemoglobin nadir were 58 × 103/µL (24–108) and 7.7 g/dL (7.1–7.9), respectively. All cases presented acute kidney injury (AKI) with a median creatinine of 4 mg/dL (3.2–4.8) and 54.5% required acute dialysis. Eculizumab was started after a median time of 8 days (6–14) with a median duration of 3 weeks (2–8). Complete TMA response was observed in 7 (63.6%) cases and hematologic response in 10 (90.9%). The time to hematologic and renal response was 23 days (13–29) and 28 days (14–46), respectively.ConclusionsTMA after LT is infrequent but potentially devastating. Our findings suggest that short cycles of eculizumab may be effective for severe TMA after LT. 10.1111/ctr.15443 http://onlinelibrary.wiley.com/termsAndConditions#vor |
| doi_str_mv | 10.1111/ctr.15443 |
| format | Artículo Open Access |
| id | wiley_oa_10_1111_ctr_15443 |
| institution | Wiley Open Access |
| license_str_mv | http://onlinelibrary.wiley.com/termsAndConditions#vor |
| publishDate | 2024 |
| publisher | Wiley |
| record_format | wiley_oa |
| spellingShingle | Eculizumab as Salvage Treatment for Thrombotic Microangiopathy After Lung Transplantation Hernando Trujillo Ana Huerta Rodrigo Alonso Maria Luisa Serrano Myriam Aguilar Enrique Morales Teresa Cavero Clinical Transplantation Eculizumab as Salvage Treatment for Thrombotic Microangiopathy After Lung Transplantation Hernando Trujillo Ana Huerta Rodrigo Alonso Maria Luisa Serrano Myriam Aguilar Enrique Morales Teresa Cavero Clinical Transplantation ABSTRACTBackgroundThrombotic microangiopathy (TMA) is a rare complication after lung transplantation (LT) that has seldom been characterized in detail. Recent evidence has linked TMA other than primary atypical hemolytic uremic syndrome (aHUS) with hyperactivation of the complement alternative pathway. The focus of this investigation was to analyze the treatment response with eculizumab in TMA after LT.MethodsCase series where we have studied 11 patients with TMA after LT from 2 Spanish tertiary healthcare centers. Clinical data and response rates to eculizumab are provided.ResultsThe main indication for lung transplant was chronic obstructive pulmonary disease (COPD) (36%) and most cases (82%) received bilateral LT. The median time to TMA diagnosis was 11.6 months (4.7–28.9) and the TMA trigger in the majority of cases (73%) was immunosuppressive drugs. Platelet and hemoglobin nadir were 58 × 103/µL (24–108) and 7.7 g/dL (7.1–7.9), respectively. All cases presented acute kidney injury (AKI) with a median creatinine of 4 mg/dL (3.2–4.8) and 54.5% required acute dialysis. Eculizumab was started after a median time of 8 days (6–14) with a median duration of 3 weeks (2–8). Complete TMA response was observed in 7 (63.6%) cases and hematologic response in 10 (90.9%). The time to hematologic and renal response was 23 days (13–29) and 28 days (14–46), respectively.ConclusionsTMA after LT is infrequent but potentially devastating. Our findings suggest that short cycles of eculizumab may be effective for severe TMA after LT. 10.1111/ctr.15443 http://onlinelibrary.wiley.com/termsAndConditions#vor |
| title | Eculizumab as Salvage Treatment for Thrombotic Microangiopathy After Lung Transplantation |
| topic | Clinical Transplantation |
| url | https://onlinelibrary.wiley.com/doi/10.1111/ctr.15443 |